

**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove some multiple dependencies and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments.

- Claims 1-7, 12 and 14-20 have been cancelled.
- The wording of the dependencies of claims 10 and 11 has been slightly amended and claim 21 has been added. This claim is a singly dependent version of original claim 10.
- The dependency of claim 13 has been altered.
- Claim 22 has been added. Basis for this claim is to be found on page 12, lines 11-15 of the published PCT specification and original claim 14.
- Claims 23-27 have been added. Basis for these claims are original claims 16-20 respectively.
- Claim 28 has been added. Basis for this claim is to be found on page 11, lines 25-29 of the published PCT application and original claims 1-3.
- Claims 29-36 have been added. These claims correspond to original claims 4-7.


The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231,

referencing Attorney Docket No. 100853 US-1.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Lucy Padget", written over a horizontal line.

Name: Lucy Clare Padget  
Dated: April 4, 2005  
Reg. No.: Limited Recognition  
Under 37 CFR §11.9(b)  
Phone No.: 781-839-4182

Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham, MA 02451